SOUTHLAKE, Texas, October 10, 2023 (PR NEWSWIRE) – Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced participation in the following upcoming investor conferences:
- 3rd Annual Needham Private Biotech Company Virtual 1×1 Forum, October 17-18, 2023
- Stifel 2023 Healthcare Conference, November 14-15, 2023, NY
Renibus management will be available to meet with investors one-on-one during these events.
Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardiorenal and metabolic diseases. Renibus’ first-in-class lead program is RBT-1, a drug that will enter a Phase 3 pivotal trial in cardiothoracic surgery in Q4 2023. RBT-3 is a novel, low molecular weight iron nanoparticle that has the potential to rapidly resolve iron deficiency and may reduce the risk of cisplatin-induced nephrotoxicity. RBT-9 (stannic protoporfin) is a potent anti-inflammatory and antioxidant drug with broad spectrum anti-viral properties. It has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. The data from this trial indicated the RBT-9 has the potential to significantly improve clinical outcomes in life threatening viral infections. Additional pre-clinical work is underway to help inform the clinical development strategy.
For more information, please visit the Company’s website at www.Renibus.com and engage with us on LinkedIn.
Investor and Media Contact:
Business Development Contact